Depletion of protein kinase C (PKC) by 12- O -tetradecanoylphorbol-13-acetate (TPA) enhances platinum drug sensitivity in human ovarian carcinoma cells
2000
Enhancing Platinum Drug Sensitivity in Ovarian Cancer Cells
publication
Author Information
Author(s): Isonishi S, Ohkawa K, Tanaka T, Howell S B
Primary Institution: Jikei University School of Medicine
Hypothesis
Depletion of protein kinase C (PKC) by TPA enhances platinum drug sensitivity in human ovarian carcinoma cells.
Conclusion
Down-regulating PKC with TPA significantly increases the sensitivity of ovarian cancer cells to platinum drugs.
Supporting Evidence
- TPA enhances sensitivity to platinum drugs by two- to threefold.
- Maximum sensitization effect was achieved with a 48-hour TPA pretreatment.
- PKCĪ± is the isoform responsive to TPA in these cells.
Takeaway
Using a special chemical called TPA makes cancer cells more sensitive to certain medicines, helping them work better.
Methodology
The study involved treating ovarian carcinoma cells with TPA and measuring changes in drug sensitivity and PKC expression.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website